Medtech start-up Strongroom AI has lost its bid for a court order blessing its proposal to sell the company to SRSPV Pty Ltd prior to a second creditors meeting.
A class action has been filed against the State of Queensland on behalf of First Nations people alleging inadequate healthcare and substandard medical treatment.
A judge has refused an eleventh-hour application by administrators for Strongroom AI for court approval of a sale offer ahead of a second creditors meeting, likening the bid to “putting a gun to the court’s head”.
A judge has refused to stay a lease dispute between landlord Dexus and South Australia’s premium medical research centre in favour of a contractual dispute resolution mechanism, saying it would be “unjust” to deprive Dexus of a court hearing.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Biopharmaceutical company Amgen has lodged proceedings against generic maker Sandoz, calling for documents related to regulatory approval of a generic version of its top-selling bone disease treatments.
Drug giant Sanofi has failed in its appeal of a decision granting applications by biopharmaceutical company Amgen for patents covering the cholesterol-lowering treatment Repatha.
Real estate landlord Dexus is suing South Australia’s medical research insitute for failing to execute on 30-year leases to occupy Adelaide’s Australian Bragg Centre, despite “repeated demands”.
Medibank has been ordered to give a class action copies of reports by Deloitte into a massive data breach in October 2022, in a judgment made public on Friday and already facing appeal by the health insurer.
A unit of collapsed start-up StrongRoom AI has warned creditors of its parent company that recent freezing orders need to be tweaked to allow it to continue trading, or there may be little money left to argue over.